MA27728A1 - Antagonistes des recepteurs de cgrp - Google Patents

Antagonistes des recepteurs de cgrp

Info

Publication number
MA27728A1
MA27728A1 MA28550A MA28550A MA27728A1 MA 27728 A1 MA27728 A1 MA 27728A1 MA 28550 A MA28550 A MA 28550A MA 28550 A MA28550 A MA 28550A MA 27728 A1 MA27728 A1 MA 27728A1
Authority
MA
Morocco
Prior art keywords
cgrp
antagonists
compounds
cgrp receptors
involved
Prior art date
Application number
MA28550A
Other languages
English (en)
Inventor
Christopher S Burgey
Zhengwu J Deng
Diem N Nguyen
Daniel V Paone
Anthony W Shaw
Theresa M Williams
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA27728A1 publication Critical patent/MA27728A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EXTRAIT La présente invention vise les composés de la Formule (I): (oé les variables R1, R2 et R3 sont telles que définies dans ces présentes) utiles comme antagonistes des récepteurs de CGRP et utiles pour le traitement ou la prévention des maladies dans lesquelles le CGRP est impliqué, comme le mal de tête, la migraine ou le névralgisme facial. L'invention vise également des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et compositions dans la prévention ou le traitement de ces maladies dans lesquelles le CGRP est impliqué.
MA28550A 2003-04-15 2005-10-11 Antagonistes des recepteurs de cgrp MA27728A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46308903P 2003-04-15 2003-04-15
US51035203P 2003-10-10 2003-10-10

Publications (1)

Publication Number Publication Date
MA27728A1 true MA27728A1 (fr) 2006-01-02

Family

ID=33303112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28550A MA27728A1 (fr) 2003-04-15 2005-10-11 Antagonistes des recepteurs de cgrp

Country Status (32)

Country Link
US (6) US6953790B2 (fr)
EP (2) EP2039694B1 (fr)
JP (1) JP3967766B2 (fr)
KR (1) KR100769030B1 (fr)
CN (1) CN100384843C (fr)
AR (1) AR045887A1 (fr)
AT (1) ATE413400T1 (fr)
AU (1) AU2004230926B2 (fr)
BR (1) BRPI0409601A (fr)
CA (1) CA2522220C (fr)
CL (1) CL2004000788A1 (fr)
CO (1) CO5640130A2 (fr)
CY (1) CY1108714T1 (fr)
DE (1) DE602004017608D1 (fr)
DK (1) DK1638969T3 (fr)
EC (1) ECSP056097A (fr)
ES (1) ES2314417T3 (fr)
HR (1) HRP20080666T3 (fr)
IS (1) IS2759B (fr)
JO (1) JO2355B1 (fr)
MA (1) MA27728A1 (fr)
MX (1) MXPA05011166A (fr)
NO (1) NO327655B1 (fr)
NZ (1) NZ543357A (fr)
PE (1) PE20050020A1 (fr)
PL (1) PL1638969T3 (fr)
PT (1) PT1638969E (fr)
RU (1) RU2308458C2 (fr)
SI (1) SI1638969T1 (fr)
TW (1) TWI314931B (fr)
UA (1) UA82877C2 (fr)
WO (2) WO2004092168A1 (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616539T3 (es) * 2002-06-05 2017-06-13 Bristol-Myers Squibb Company Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
WO2004091514A2 (fr) * 2003-04-15 2004-10-28 Merck & Co., Inc. Antagonistes des recepteurs de cgrp
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
US7476665B2 (en) * 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
EP1641781B1 (fr) * 2003-06-26 2013-03-06 Merck Sharp & Dohme Corp. Antagonistes du récepteur CGRP de benzodiazépine
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
CN101124217A (zh) * 2004-01-29 2008-02-13 默克公司 Cgrp受体拮抗剂
AU2005217642B2 (en) * 2004-02-23 2012-04-12 Trustees Of Tufts College Lactams as conformationally constrained peptidomimetic inhibitors
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7659264B2 (en) * 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
DE602005027870D1 (de) 2004-10-14 2011-06-16 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2423085C (en) * 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
GB2467060B (en) * 2005-02-11 2010-09-01 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
EP1861399B1 (fr) * 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Antagonistes du recepteur du cgrp
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
CN100371327C (zh) * 2005-11-17 2008-02-27 江苏工业学院 2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
EP1954135B1 (fr) * 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Antagonistes du récepteur cgrp spirolactame-aryle
AU2007238894A1 (en) * 2006-04-10 2007-10-25 Merck Sharp & Dohme Corp. Process for the preparation of pyridine heterocycle CGRP antagonist intermediate
WO2007120589A2 (fr) * 2006-04-10 2007-10-25 Merck & Co., Inc. Procédé de préparation d'un intermédiaire antagoniste du peptide cgrp de caprolactame
EP2007764B1 (fr) 2006-04-10 2009-08-26 Merck & Co., Inc. Procédé de préparation d'un antagoniste cgrp
WO2007120592A1 (fr) * 2006-04-10 2007-10-25 Merck & Co., Inc. Sel antagoniste de cgrp
EP2013213B1 (fr) 2006-05-02 2011-07-27 Bristol-Myers Squibb Company Utilisation de composés contraints en tant qu'antagonistes des récepteurs cgrp
US7470680B2 (en) * 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
WO2007133491A1 (fr) * 2006-05-09 2007-11-22 Merck & Co., Inc. Antagonistes de récepteurs cgrp monocycliques substitués
EP2027106A2 (fr) * 2006-06-13 2009-02-25 Vertex Pharmaceuticals Incorporated Antagonistes du récepteur du cgrp
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
BRPI0714725B1 (pt) * 2006-08-02 2021-05-25 Cytokinetics, Inc Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AU2007293032A1 (en) * 2006-09-08 2008-03-13 Merck Sharp & Dohme Corp. Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
HRP20120240T1 (hr) 2007-05-23 2012-04-30 Merck Sharp & Dohme Corp. Piridil piperidin antagonisti receptora za oreksin
GB0712392D0 (en) * 2007-06-26 2007-08-01 Glaxo Group Ltd Novel compounds
US20090075977A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk0974
JP2011511792A (ja) * 2008-02-05 2011-04-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニストのプロドラッグ
JP2011512410A (ja) 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト
KR101304150B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
KR20110025926A (ko) * 2008-06-30 2011-03-14 머크 샤프 앤드 돔 코포레이션 텔카게판트 칼륨의 고체 투여 제형
AU2009307921A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI501968B (zh) 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
CA2830348A1 (fr) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Antagonistes spirohydantoines des recepteurs cgrp de type carboxamide de piperidine
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
EA033109B1 (ru) 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
PT3495392T (pt) 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RS56556B1 (sr) 2012-02-27 2018-02-28 Bristol Myers Squibb Co N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so
WO2013144187A1 (fr) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Dérivés de 5-aminopyridine et utilisation desdits dérivés pour la lutte contre la croissance de plantes indésirables
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
WO2017001434A1 (fr) * 2015-06-29 2017-01-05 Galderma Research & Development Composés de type antagonistes des récepteurs du cgrp pour traitement par voie topique de maladies de la peau
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
EP3366286A1 (fr) 2017-02-22 2018-08-29 Johannes Keller Composés destinés au traitement de septicémie
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN108892635A (zh) * 2018-09-07 2018-11-27 江苏工程职业技术学院 一种西沙必利关键中间体的制备方法
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
GEAP202515803A (en) 2019-05-02 2025-06-10 H Lundbeck As Treatment of headache using anti-cgrp antibodies
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
GB201908420D0 (en) 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3206184A1 (fr) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Traitement de la migraine
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2023026205A1 (fr) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Traitement préventif de la migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
CN116903616B (zh) * 2023-07-17 2025-08-01 江西同和药业股份有限公司 一种瑞美吉泮中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
WO1996035713A1 (fr) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides stimulant la liberation de l'hormone de croissance
JP2002525371A (ja) * 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
KR20010075447A (ko) 1998-09-30 2001-08-09 우에하라 아끼라 치환 이속사졸릴 티오펜 화합물
ES2616539T3 (es) * 2002-06-05 2017-06-13 Bristol-Myers Squibb Company Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
WO2004091514A2 (fr) * 2003-04-15 2004-10-28 Merck & Co., Inc. Antagonistes des recepteurs de cgrp

Also Published As

Publication number Publication date
US7452903B2 (en) 2008-11-18
WO2004092168A1 (fr) 2004-10-28
DE602004017608D1 (de) 2008-12-18
US20040229861A1 (en) 2004-11-18
AR045887A1 (es) 2005-11-16
US7772224B2 (en) 2010-08-10
ATE413400T1 (de) 2008-11-15
MXPA05011166A (es) 2005-12-14
EP2039694A1 (fr) 2009-03-25
AU2004230926A1 (en) 2004-10-28
RU2005135440A (ru) 2006-03-20
KR100769030B1 (ko) 2007-10-22
BRPI0409601A (pt) 2006-04-18
WO2004092166A2 (fr) 2004-10-28
CA2522220C (fr) 2009-06-23
PT1638969E (pt) 2009-01-16
JO2355B1 (en) 2006-12-12
TW200505903A (en) 2005-02-16
HRP20080666T3 (en) 2009-01-31
JP3967766B2 (ja) 2007-08-29
PL1638969T3 (pl) 2009-04-30
US7235545B2 (en) 2007-06-26
US7893052B2 (en) 2011-02-22
KR20050121734A (ko) 2005-12-27
WO2004092166A3 (fr) 2005-01-20
CO5640130A2 (es) 2006-05-31
TWI314931B (en) 2009-09-21
US20090192139A1 (en) 2009-07-30
SI1638969T1 (sl) 2009-02-28
US20100298303A1 (en) 2010-11-25
PE20050020A1 (es) 2005-02-18
UA82877C2 (en) 2008-05-26
US20070225272A1 (en) 2007-09-27
JP2006523697A (ja) 2006-10-19
EP1638969A2 (fr) 2006-03-29
CN1802376A (zh) 2006-07-12
ES2314417T3 (es) 2009-03-16
EP1638969B1 (fr) 2008-11-05
US20050256098A1 (en) 2005-11-17
IS8055A (is) 2005-09-29
US20080280857A1 (en) 2008-11-13
CN100384843C (zh) 2008-04-30
RU2308458C2 (ru) 2007-10-20
CL2004000788A1 (es) 2005-02-25
IS2759B (is) 2011-10-15
HK1090922A1 (en) 2007-01-05
US6953790B2 (en) 2005-10-11
NZ543357A (en) 2008-08-29
DK1638969T3 (da) 2009-01-26
CA2522220A1 (fr) 2004-10-28
EP2039694B1 (fr) 2014-03-26
AU2004230926B2 (en) 2008-07-17
ECSP056097A (es) 2006-03-01
US7534784B2 (en) 2009-05-19
NO20055375L (no) 2005-11-14
NO327655B1 (no) 2009-09-07
CY1108714T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
TW200505903A (en) CGRP receptor antagonists
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
WO2005013894A3 (fr) Antagonistes du recepteur du cgrp de
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
ATE466860T1 (de) Cgrp-rezeptorantagonisten
DE602004013563D1 (de) Rantagonisten
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
EP1606286A4 (fr) Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
MA31683B1 (fr) Composes et procedes pour moduler fxr
EP1606264A4 (fr) Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique
MA30558B1 (fr) Antagonistes de recepteurs cgrp monocycliques substitues
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
ATE535514T1 (de) Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
EP1793827A4 (fr) Antagonistes des recepteurs cgrp sous forme de spirolactame d'anilide tricyclique
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
IL182317A0 (en) Cgrp receptor antagonists
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
MA31894B1 (fr) Composes organiques
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
ATE503755T1 (de) Cgrp-rezeptorantagonisten
MA68743B1 (fr) Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa